In reconciling these observations, we determined that the putative IL13Rα2-specific antibody B-D13 recognizes VCAM-1, and that cytokine induction is not a viable approach to increase cell surface expression of IL13Rα2 for therapeutic targeting of gliomas. Here, IL13RA2 is linked to central nervous system cancer.